Late-Breaking Phase 3 Data From AAO Retina Subspecialty Day
Brolucizumab (Beovu, Novartis) was approved by the US FDA for the treatment of wet AMD. But how does it affect patients with polypoidal choroidal vasculopathy? Glenn Jaffe, MD, joins the podcast to discuss a substudy in the phase 3 HAWK trial that aimed to find out. Also, as the FDA reviews a new drug application for abicipar pegol (Allergan), what can we learn from the phase 3 trials CEDAR and SEQUOIA now that the 2-year data were released? Rahul Khurana, MD, details his presentation live from the BMC booth.